Let’s Go Down the Correct Path(way)

To the Editor:

“Acquired Liver Injury in the Intensive Care Unit” by Lescot et al.1 is an excellent discussion of the multifaceted causes of liver injury. One correction is in order, however. The review incorrectly states that the international normalized ratio reflects intrinsic pathway activity. It is the activity of the extrinsic coagulation pathway, often now referred to as the tissue factor pathway, that is measured by the international normalized ratio and initiates the coagulation cascade.2 An understanding of the specific pathway measured by a coagulation test is paramount to the treatment of defects secondary to liver disease. It should also be pointed out that the international normalized ratio, one component of the model for end-stage liver disease scoring used to prioritize liver transplantation waiting lists, can be highly variable depending on the laboratory analyzing the sample.3

Matthew R. Johnson, M.D., Mark J. Rice, M.D.*University of Florida College of Medicine, Gainesville, Florida. mrice@anest.ufl.edu

References


(Accepted for publication January 23, 2013.)

In Reply:

We thank Drs. Johnson and Rice for correcting our inadvertent error from our article1 and agree with their comments.

Thomas Lescot, M.D., Ph.D.,* Constantine Karvellas, M.D., F.R.C.P.C., Marc Beaussier, M.D., Ph.D., Sheldon Magder, M.D., F.R.C.P.C. *Royal Victoria Hospital, McGill University Health Center, Montreal, Quebec, Canada. thomas.lescot@sat.aphp.fr

Reference


(Accepted for publication January 23, 2013.)

Intralipid: The New Magic Bullet in Cardioprotection?

To the Editor:

In two recent publications in Anesthesiology, Dr. Eghbali’s group reports the attenuation of myocardial reperfusion injury in rodents by intralipid administered on reperfusion.1,2 Taken together with another study by the same group in which intralipid prevents and even rescues bupivacaine-induced cardiotoxicity first in dogs4 and then humans,5 intralipid appears to have become a new magic bullet for cardioprotection. Nevertheless, many questions remain. Li et al.6 state that intralipid acts through the phosphorylation of Akt/extracellular signal-regulated kinase-1/glycogen

Research funding provided in part by the Department of Veterans Affairs, Washington, D.C. (CARA-026-10F to M.L.R.), the National Institutes of Health, Bethesda, Maryland (5R01 HL098400-03 to M.L.R. and NIH R01 HL092071 to M.V.P.), and institutional funds.

(March 29, 2013.)

In Reply:
We thank Drs. Reiss and Podgoreanu for highlighting our recent findings1–4 on intralipid and raising all these important questions about the mechanisms underlying the cardioprotective action of one of the most promising agents.

In the acute cardioprotective action of intralipid as in ischemia–reperfusion injury5 and bupivacaine overdose,6 inhibition of mitochondrial permeability transition pore opening seems to be one of the key mechanisms. We found that inhibition of mPTP by intralipid is due to increased phosphorylation of glycogen synthase kinase 3 beta and/or decreased pH by improving mitochondrial electron transport chain function through fatty acid oxidation pathway.7 The fact that cyclosporine-A, which inhibits the opening of the mPTP as efficiently as intralipid, is not able to reduce the infarct size and improve the heart function as intralipid,8 may suggest that inhibition of mPTP opening, although necessary, certainly is not the only mechanism underlying intralipid-induced cardioprotection. However, it is important to note that the effect of cyclosporine-A on the mPTP is not selective, because cyclosporine-A can also inhibit the phosphatase calcineurin activity.8 This interaction of cyclosporine-A with phosphatase calcineurin is independent of its action on mPTP.9 However, it is possible that the effect of cyclosporine-A on calcineurin may limit the cyclosporine-A-induced cardioprotection. Therefore, to clarify whether there is a correlation between the degree of functional and tissue protection with inhibition of mPTP opening, intralipid must be compared with a nonimmunosuppressive cyclosporine-A

References


Support was provided by National Institutes of Health (Bethesda, Maryland) grant HL089876.